Methods for treating HCV

• US 8,492,386 B2
• Filed: 09/04/2012
• Issued: 07/23/2013
• Est. Priority Date: 10/21/2011
• Status: Active Grant

• Current Assignee: Abbvie Incorporated
• Original Assignee: Abbvie Incorporated
• Inventors: Bernstein, Barry M., Menon, Rajeev M., Khatri, Amit, Mensing, Sven, Dutta, Sandeep, Cohen, Daniel E., Podsadecki, Thomas J., Brun, Scott C., Awni, Walid M., Dumas, Emily O., Klein, Cheri E.
• Primary Examiner(s): Wang, Shengjun
• Application Number:
  US13/603,006
• Publication Number:
  US 20130102558A1
• Time in Patent Office: 322 Days
• Field of Search: 514/183, 514/269, 514/314, 514/397, 514/309, 514/394, 514/81, 514/274, 514/255.05, 514/422
• US Class Current: 514/255.05
• CPC Class Codes: A61K 31/4025 not condensed and containing further heterocyclic rings, e.g. cromakalim
• CPC Class Codes: A61K 31/4184 condensed with carbocyclic rings, e.g. benzimidazoles
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/473 ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• CPC Class Codes: A61K 31/513 having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
• CPC Class Codes: A61K 31/7072 having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
• CPC Class Codes: A61K 38/05 Dipeptides
• CPC Class Codes: A61K 38/06 Tripeptides
• CPC Class Codes: A61K 38/07 Tetrapeptides
• CPC Class Codes: A61K 38/12 Cyclic peptides , e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/14 for RNA viruses
• CPC Class Codes: G06F 17/10 Complex mathematical operations function generation by table look-up G06F1/03; evaluation of elementary functions by calculation G06F7/544
• CPC Class Codes: G16B 5/00 ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Abstract

The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir).

Claims

1. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribaviron to said patient, and said treatment lasts for 12 weeks, and wherein said at least two DAAs comprise:

Compound 1 having formula of

2. The method of claim 1, wherein said patient is a treatment-naï

ve patient.

3. The method of claim 1, wherein said at least two DAAs further comprise compound 2 having formula of

4. The method of claim 2, wherein said at least two DAAs further comprise compound 2 having formula of

5. The method of claim 1, wherein said patient is infected with HCV genotype 1a.

6. The method of claim 2, wherein said patient is infected with HCV genotype 1a.

7. The method of claim 3, wherein said patient is infected with HCV genotype 1a.

8. The method of claim 4, wherein said patient is infected with HCV genotype 1a.

9. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribavirin to said patient, wherein said at least two DAAs comprise PSI-7977 and TMC-435, and wherein said treatment lasts for 12 weeks.

10. The method of claim 9, wherein said patient is a treatment-naï

ve patient.

11. The method of claim 9, wherein said patient is infected with HCV genotype 1a.

12. The method of claim 10, wherein said patient is infected with HCV genotype 1a.

13. A method of treatment for HCV, comprising administering at least two direct acting antiviral agents (DAAs) to an HCV patient infected with HCV genotype 1, wherein said treatment does not include administration of either interferon or ribavirin to said patient, wherein said at least two DAAs comprise PSI-7977 and GS-5885, and wherein said treatment as for 12 weeks.

14. The method of claim 13, wherein said patient is a treatment-naï

ve patient.

15. The method of claim 13, wherein said patient is infected with HCV genotype 1a.

16. The method of claim 14, wherein said patient is infected with HCV genotype 1a.